Peringkat dalam Saham
#41235
GENinCode Plc specializes in the creation and commercialization of advanced... GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Kapitalisasi Pasar
$34.25K
Perubahan (1 tahun)
-39.87%
Perdagangan GENinCode plc (GENI)
Laba untuk GENinCode plc (GENI)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari GENinCode plc, laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk GENinCode plc dari 2026 hingga 2026
Laba pada akhir setiap tahun
| Tahun |
Laba |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Laba untuk perusahaan serupa atau pesaing
| Perusahaan |
Laba |
Perbedaan Laba |
Negara |
|
|
$7.61B |
-
|
US
|
|
|
$4.76B |
-
|
US
|
|
|
- |
-
|
CN
|
|
|
$-252.70M |
-
|
US
|
|
|
$1.42B |
-
|
US
|